Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 7/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694643 | 1.00 | KDM4E (0.57) | KDM4EMAPK1ESR1ESR2HCAR2 | |
| SCHEMBL5694682 | 0.81 | ESR1 (0.62) | KDM4EMAPK1ESR1ESR2HCAR2 | |
| SCHEMBL5694679 | 0.81 | ESR1 (0.62) | KDM4EMAPK1ESR1ESR2HCAR2 | |
| SCHEMBL5694714 | 0.80 | CA12 (0.61) | ESR1CA12AKR1B10CA1CA2 | |
| SCHEMBL5694708 | 0.80 | CA12 (0.61) | ESR1CA12AKR1B10CA1CA2 | |
| SCHEMBL18712219 | 0.78 | ESR1 (0.61) | KDM4EMAPK1ESR1ESR2HCAR2 | |
| SCHEMBL3458123 | 0.78 | ESR1 (0.61) | KDM4EMAPK1ESR1ESR2HCAR2 | |
| SCHEMBL3458120 | 0.78 | ESR1 (0.61) | KDM4EMAPK1ESR1ESR2HCAR2 | |
| Cinnamic Acid SCHEMBL363485 | 0.78 | HCAR2 (0.66) | KDM4EMAPK1ESR1ESR2HCAR2 | |
| SCHEMBL3617907 | 0.78 | ESR1 (0.55) | KDM4EMAPK1ESR1ESR2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| EP-1094055-B1 | NOVEL VINYLBENZENE DERIVATIVES | SANTEN PHARMACEUTICAL CO LTD (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-6329547-B1 | USEFUL AS THERAPEUTIC AGENTS FOR GLAUCOMA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1094055-A1 | NOVEL VINYLBENZENE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | KDM4E 4836/4885MAPK1 3536/4885ESR1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.